Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 57, Issue 1, 2013, Pages 35-38

  Adler, Jeremy ^a   Sandberg, Kelly C ^a   Shpeen, Benjamin H ^a   Eder, Sally J ^a   Dhanani, Muhammad ^b   Clark, Sarah J ^a   Freed, Gary L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Drug dosing; Inflammatory bowel disease; Infliximab, survey

Indexed keywords

CORTICOSTEROID; INFLIXIMAB;

ARTICLE; ENTERITIS; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NURSE PRACTITIONER; OUTCOME ASSESSMENT; PHYSICIAN; PHYSICIAN ASSISTANT; PREMEDICATION; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; DRUG DOSAGE CALCULATIONS; DRUG HYPERSENSITIVITY; GASTROINTESTINAL AGENTS; HEALTH CARE SURVEYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; LONDON; PHYSICIAN'S PRACTICE PATTERNS; PREMEDICATION; UNITED STATES; VOLUNTARY HEALTH AGENCIES;

EID: 84975159140     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31828f1ea2     Document Type: Article

References (9)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359: 1541-9.
2. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132: 863-73.
3. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295: 2275-85.
4. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
5. de Vries HS, van Oijen MG, Driessen RJ, et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol 2011;71: 7-19.
6. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4: 621-30.
7. Siegel CA. Comprehensive approach to patient risk: risks versus benefits of immunomodulators and biologic therapy for inflammatory bowel disease. In: Targan S, Shanahan F, Karp LC, eds. Inflammatory Bowel Disease: Translating Basic Science into Clinical Practice. West Sussex, UK: Blackwell Publishing Ltd; 2010.
8. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124: 917-24.
9. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005;11: 442-6.